Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Medicine
|
October 30, 2015
A Simple Evaluation Tool (ET-CET) Indicates Increase of Diagnostic Skills From Small Bowel Capsule Endoscopy Training Courses: A Prospective Observational European Multicenter Study
J G Albert, O Humbla, M E McAlindon, et al.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 9, 2022
Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG)
D Martin, T Schreckenbach, P Ziegler, et al.
ESMO Open
|
April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
P Meyer-Wilmes, J Huober, M Untch, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Medicine
|
October 30, 2015
A Simple Evaluation Tool (ET-CET) Indicates Increase of Diagnostic Skills From Small Bowel Capsule Endoscopy Training Courses: A Prospective Observational European Multicenter Study
J G Albert, O Humbla, M E McAlindon, et al.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 9, 2022
Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG)
D Martin, T Schreckenbach, P Ziegler, et al.
ESMO Open
|
April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
P Meyer-Wilmes, J Huober, M Untch, et al.
Page
of 2